Clinical trials: Platelet Reactivity
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Platelet Reactivity
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
Platelets are a major component of clot formation which can lead to clotting events such as heart attack. During treatment for a heart attack, doctors try to remove this blockage as quickly as possible so that the heart can…
- Trial name
- NCT00827346
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Stroke
Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research
The investigators want to verify whether mobile application based on stroke strengthen prevention management is more effective than traditional management model or open stroke management platform.
- Trial name
- NCT02618265
- Testing
- Mobile terminal, traditional management, website platform management
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University Third Hospital
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Fetal and Neonatal Alloimmune Thrombocytopenia, Long Term Adverse Effects
Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a disease caused by allo-immunisation during pregnancy. If left untreated, FNAIT can lead to severe fetal intracranial haemorrhage.
- Conditions
- Fetal and Neonatal Alloimmune Thrombocytopenia, Long Term Adverse Effects, Neurodevelopmental Abnormality, Intravenous Immunoglobulin Adverse Reaction
- Trial name
- NOFNAIT (NCT04529382)
- Testing
- Cognitive testing (Bayley III, WPPSI III and WISC V)
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Leiden University Medical Center
Coronary Artery Disease
Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
No previous study has assessed the potential of ranolazine to interfere with levels of platelet reactivity in patients with coronary artery disease who are treated with dual antiplatelet therapy.
- Trial name
- ROMAN (NCT01490255)
- Testing
- Ranolazine, Amlodipine
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Transfusion Related Acute Lung Injury
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
This study is a prospective, non-randomized sequential cohort, open label, multi-center, non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs.
- Trial name
- PIPER (NCT02549222)
- Testing
- Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 2,291 people
- Sponsor
- Cerus Corporation
Myocardial Infarction
Novel Biomarkers of Thrombotic Risk
Treatment of patients who have had a heart attack with drugs that prevent formation of blood clots has been shown to reduce the patient's risk of subsequent cardiovascular events such as heart attack, stroke, and death.
- Trial name
- NCT02505217
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Vermont
Stable Angina
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity…
- Trial name
- ACHIDO (NCT01335048)
- Testing
- atorvastatin and clopidogrel, Clopidogrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale Misericordia e Dolce
Diabetes Mellitus, Complication of Coronary Artery Bypass Graft
Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery
The aim of this study is to evaluate whether increased level of hemoglobin A1c (HbA1c) correlates to higher level of platelet reactivity assessed by impedance aggregometry in patients with diabetes mellitus undergoing elective…
- Conditions
- Diabetes Mellitus, Complication of Coronary Artery Bypass Graft, Blood Platelet Disorders
- Trial name
- NCT02711124
- Where
- Croatia
- Volunteers
- 130 people
- Sponsor
- Clinical Hospital Centre Zagreb
Antineoplastic Adverse Reaction, Thrombocytopenia
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
Chemotherapy-related myelosuppression usually occurs in AML patients, which induces severe thrombocytopenia and haemorrhage, a leading cause of death.
- Conditions
- Antineoplastic Adverse Reaction, Thrombocytopenia, Acute Myelocytic Leukemia
- Trial name
- NCT02244658
- Testing
- rhTPO
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shandong University
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Extracorporeal Membrane Oxygenation Complication, Hemorrhage
ECMO Hemostatic Transfusions in Children
Critically ill children supported by extracorporeal membrane oxygenation (ECMO) receive large volumes of prophylactic platelet transfusions to prevent bleeding.
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Thromboembolism, Transfusion Adverse Reaction
- Trial name
- ECSTATIC (NCT05796557)
- Testing
- Platelet Transfusion
- Where
- 10 sites in United States, Israel
- Volunteers
- 50 people
- Sponsor
- Yale University
Anaphylaxis, Allergy
Mechanisms of Anaphylaxis
The purpose of this study is to explore different mechanisms for anaphylaxis and find novel biomarkers for this hypersensitivity syndrome.
- Conditions
- Anaphylaxis, Allergy, Transfusion Reaction, Febrile Transfusion Reaction
- Trial name
- ANAMEK (NCT03182491)
- Testing
- Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
- Where
- Norway
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective…
- Conditions
- Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- ISS-DMII (NCT03258281)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Inova Health Care Services